LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

Stock Information for Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A)

LakeShore Biopharma Announces US$15 Million Private Placement Financing
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA(TM) Rabies Vaccine (Vero Cell)
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.